Plerixafor on‐demand combined with chemotherapy and granulocyte colony‐stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

Summary To date, no prospective study on Plerixafor ‘on‐demand’ in combination with chemotherapy and granulocyte colony‐stimulating factor (G‐CSF) has been reported. We present an interim analysis of the first prospective study in which Plerixafor was administered on‐demand in patients affected by m...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2014-01, Vol.164 (1), p.113-123
Main Authors: Milone, Giuseppe, Martino, Massimo, Spadaro, Andrea, Leotta, Salvatore, Di Marco, Annalia, Scalzulli, Potito, Cupri, Alessandra, Di Martina, Valentina, Schinocca, Elena, Spina, Eleonora, Tripepi, Giovanni
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
apheresis harvest
Biological and medical sciences
Blood Component Removal - economics
Blood Component Removal - methods
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Granulocyte Colony-Stimulating Factor - economics
Hematologic and hematopoietic diseases
Hematopoietic Stem Cell Mobilization - economics
Hematopoietic Stem Cell Mobilization - methods
Heterocyclic Compounds - administration & dosage
Heterocyclic Compounds - economics
Humans
Lymphoma - drug therapy
Lymphoma - surgery
Lymphoma - therapy
Male
Medical sciences
Middle Aged
Multiple Myeloma - drug therapy
Multiple Myeloma - surgery
Multiple Myeloma - therapy
peripheral blood stem cell mobilization
Peripheral Blood Stem Cell Transplantation - economics
Peripheral Blood Stem Cell Transplantation - methods
plerixafor
Prospective Studies
Retrospective Studies
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary To date, no prospective study on Plerixafor ‘on‐demand’ in combination with chemotherapy and granulocyte colony‐stimulating factor (G‐CSF) has been reported. We present an interim analysis of the first prospective study in which Plerixafor was administered on‐demand in patients affected by multiple myeloma and lymphoma who received high dose cyclophosphamide or DHAP (dexamethasone, cytarabine, cisplatin) plus G‐CSF to mobilize peripheral blood stem cells (PBSC). One hundred and two patients were evaluable for response. A cohort of 240 patients receiving the same mobilizing chemotherapy was retrospectively studied. Failure to mobilize CD34+ cells in peripheral blood was reduced by ‘on‐demand’ strategy compared to conventional mobilization; from 13·0 to 3·0% (P = 0·004). Failure to harvest CD34+ cells 2 × 106/kg decreased from 20·9 to 4·0% (P = 0·0001). The on‐demand Plerixafor strategy also resulted in a lower rate of mobilization failure (P = 0·03) and harvest failure (P = 0·0008) when compared to a ‘bias‐adjusted set of controls’. Evaluation of economic costs of the two strategies showed that the overall cost of the two treatments were comparable when salvage mobilizations were taken into account. When in combination with cyclophosphamide or DHAP plus G‐CSF, the ‘on‐demand’ use of Plerixafor showed, in comparison to conventionally treated patients, a significant improvement in mobilization of PBSC with no increase in overall cost.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.12606